Patents by Inventor Michael E. Garst

Michael E. Garst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9371278
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 9351948
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: May 31, 2016
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS
    Publication number: 20160137616
    Abstract: The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 19, 2016
    Inventors: Ling Li, Janet A. Takeuchi, Ken Chow, Wha Bin Im, Michael E. Garst
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9328067
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 3, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20160083342
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: June 29, 2015
    Publication date: March 24, 2016
    Inventors: HAIQING YUAN, RICHARD L. BEARD, XIAOXIA LIU, JOHN E. DONELLO, VEENA VISWANATH, MICHAEL E. GARST
  • Cyclosporin A analogs
    Patent number: 9266927
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: February 23, 2016
    Assignee: Allergan, Inc.
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, William R. Carling, Michael E. Garst
  • N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
    Publication number: 20160045489
    Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventors: Santosh C. Sinha, Liming Wang, Ken Chow, Mohammed I. Dibas, Michael E. Garst
  • CYCLOSPORIN A ANALOGS
    Publication number: 20160039880
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Application
    Filed: August 12, 2015
    Publication date: February 11, 2016
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, William R. Carling, Michael E. Garst
  • Cyclosporin Analogs
    Publication number: 20160022765
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: October 2, 2015
    Publication date: January 28, 2016
    Inventors: Michael E. Garst, William Robert Carling, David Arthur Scowen, Michael E. Stern, Christopher S. Schaumburg
  • N—(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
    Patent number: 9199989
    Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: December 1, 2015
    Assignee: Allergan, Inc.
    Inventors: Liming Wang, Mohammed I. Dibas, Michael E. Garst, Ken Chow, Santosh C. Sinha
  • Cyclosporin analogs
    Patent number: 9175042
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael E. Garst, William Carling, David Scowen, Michael E. Stern, Christopher S. Schaumburg
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20150224080
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: April 21, 2015
    Publication date: August 13, 2015
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20150218119
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: January 5, 2015
    Publication date: August 6, 2015
    Inventors: HAIQING YUAN, RICHARD L. BEARD, XIAOXIA LIU, JOHN E. DONELLO, VEENA VISWANATH, MICHAEL E. GARST
  • Aromatic bycyclic derivatives as CXCR4 receptor modulators
    Patent number: 9090624
    Abstract: The present invention relates to novel aromatic bicyclic derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the CXCR4 receptor.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: July 28, 2015
    Assignee: Allergan, Inc.
    Inventors: Vidyasagar Vuligonda, Richard L. Beard, Thong Vu, John E. Donello, Gerard Rodrigues, Veena Viswanath, Michael E. Garst
  • Modulators of S1P receptors
    Patent number: 9079864
    Abstract: The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: July 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, Michael E. Garst, Wha Bin Im
  • ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS
    Publication number: 20150148394
    Abstract: The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Inventors: Mohammed I. Dibas, Daniel W. Gil, John E. Donnello, Ken Chow, Liming Wang, Michael E. Garst
  • AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
    Publication number: 20150148395
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • -(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors
    Patent number: 9034896
    Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene) Heterocyclopenta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: May 19, 2015
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Liming Wang, Ken Chow, Mohammed I. Dibas, Michael E. Garst
  • Methods of treating alpha adrenergic mediated conditions
    Patent number: 9034910
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 19, 2015
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Phosphate Esters of Bimatoprost and the Prostamides
    Publication number: 20150119367
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Application
    Filed: October 29, 2013
    Publication date: April 30, 2015
    Applicant: Allergan, Inc.
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd S. Gac, Robert M. Burk, Michael E. Garst